Clinical trial
Thalidomide in Treating Patients With Myelofibrosis
NCT00015821 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00015821 |
|---|---|
| Title | Thalidomide in Treating Patients With Myelofibrosis |
| Official title | A Pilot Study of Thalidomide as an Inhibitor of Angiogenesis in the Treatment of Myelofibrosis With Myeloid Metaplasia (MMM) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Myelofibrosis |
| Intervention type | Drug, Other |
| Interventions | thalidomide, laboratory biomarker analysis |
| Enrollment | 43 |
| Start date | May 1, 2000 |
| Primary completion | Dec 1, 2007 |
| First posted | May 23, 2003 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: